GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Asset Turnover

Lipocine (Lipocine) Asset Turnover : 0.31 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lipocine Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Lipocine's Revenue for the three months ended in Mar. 2024 was $7.62 Mil. Lipocine's Total Assets for the quarter that ended in Mar. 2024 was $24.22 Mil. Therefore, Lipocine's Asset Turnover for the quarter that ended in Mar. 2024 was 0.31.

Asset Turnover is linked to ROE % through Du Pont Formula. Lipocine's annualized ROE % for the quarter that ended in Mar. 2024 was 63.42%. It is also linked to ROA % through Du Pont Formula. Lipocine's annualized ROA % for the quarter that ended in Mar. 2024 was 58.03%.


Lipocine Asset Turnover Historical Data

The historical data trend for Lipocine's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Asset Turnover Chart

Lipocine Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.42 0.01 -0.09

Lipocine Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.11 0.01 0.31

Competitive Comparison of Lipocine's Asset Turnover

For the Biotechnology subindustry, Lipocine's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Lipocine's Asset Turnover falls into.



Lipocine Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Lipocine's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-2.851/( (37.543+23.001)/ 2 )
=-2.851/30.272
=-0.09

Lipocine's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=7.617/( (23.001+25.447)/ 2 )
=7.617/24.224
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Lipocine  (NAS:LPCN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Lipocine's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=14.056/22.1625
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(14.056 / 30.468)*(30.468 / 24.224)*(24.224/ 22.1625)
=Net Margin %*Asset Turnover*Equity Multiplier
=46.13 %*1.2578*1.093
=ROA %*Equity Multiplier
=58.03 %*1.093
=63.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Lipocine's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=14.056/24.224
=(Net Income / Revenue)*(Revenue / Total Assets)
=(14.056 / 30.468)*(30.468 / 24.224)
=Net Margin %*Asset Turnover
=46.13 %*1.2578
=58.03 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Lipocine Asset Turnover Related Terms

Thank you for viewing the detailed overview of Lipocine's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (Lipocine) Business Description

Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103